AIDX Company Profile and Key Details

20/20 Biolabs Inc. has 12.77 million shares outstanding. The public float is 10.84 million shares, elevated short interest at 0.99% of float. This equals 105.84 thousand shares. The short ratio is 0.94 days. Institutional investors hold 3.38% of the float. Insiders own 26.16%.

Short-term trend indicators are mixed aligned (SMA20 -63.3%, SMA50 -63.3%, SMA200 -63.3%). The stock remains hovering near 52-week lows, trading -91.84% below its high and over -21.84% above its low. Average 10-day trading volume of 84.90 thousand shares is below the 3-month average of 611.00 thousand, indicating normal recent market interest.

20/20 Biolabs Inc. generated EPS of $nan over the past year. Five-year average earnings growth is -17.86%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 693.65% upside. The low target suggests 693.65% downside. The mean target is $5.00. This offers 693.65% upside. 20/20 Biolabs Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by 116.67%. The prior quarter beat by 180.0%. Over the last six quarters, Apple has recorded several small beats. These include 180.0% in May 20, 2026.

Our AI price prediction model suggests that 20/20 Biolabs Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.63%, with price expected at $0.71 by September 16, 2026, within a range of $0.67 to $0.74 3-Month Outlook: Projected fall of -93.65%, reaching $0.04 by November 30, 2026, with a range of $0.01 to $0.07. 1-Year Outlook: Projected gain of 4585.91%, with price at $29.54 by September 02, 2027, within a range of $16.40 to $44.87.

currently trading near 52-week highs band. Valuation shows 20/20 Biolabs Inc. trading at a premium to the broader market with a P/E of -0.84. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 693.15% upside. Our AI forecast model points to short-term strength (12.63% over two weeks), a medium-term fall (-93.65% over three months), and a longer-term gain (4585.91% over one year), with expected trading ranges indicating moderate volatility.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

20/20 Biolabs Inc. (NASDAQ:AIDX) closed at $0.63 USD, gaining $0.01 (2.41%) from the previous close of $0.62. The stock is currently mid-range between its 52-week high and low $0.40 and $50.00. With a market capitalization of about $7.72 million, 20/20 Biolabs Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.54). Key stats such as the average daily volume over the past year has been around 637.91 thousand shares, volume is running light vs its 52-week average. Headquartered in Gaithersburg, MD, 20/20 Biolabs Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Jonathan Cohen, the company employs approximately 14 people and listed since February 19, 2026. 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services.

20/20 Biolabs Inc. trades at a P/E ratio of -0.84, slightly below the S&P 500 average, with a price-to-sales ratio of 3.84 and a price-to-book ratio of 2.19 suggesting the stock is closer to book value. The P/FCF stands at -2.81, also below market averages.